ArticleBiochemistry and biophysics reports2026
Virus-like particles vaccine of porcine epidemic diarrhea virus spike 1 protein induces protective immunity challenge in piglets.
Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Porcine epidemic diarrhea virus (PEDV) is a highly contagious intestinal disease that impairs piglet growth and development, causing significant economic losses. Therefore, developing an effective vaccine is crucial for preventing and controlling PEDV. This study used a eukaryotic expression system to assemble S1 with Ferritin into virus-like particles (S1-F-VLP) via SpyTag-SpyCatcher and confirmed their immunogenicity and protective efficacy. The results showed no mouse deaths or sow abortions during S1-F-VLP vaccination, confirming its safety. In mouse, sow and piglet models, S1-F-VLP vaccination induced high levels of PEDV-specific antibodies including serum IgG, IgA (IgA) and neutralizing antibodies (NAbs). The piglet challenge test results showed that, compared with the control group, S1-F-VLP-vaccinated piglets had significantly lower diarrhea score and intestinal viral loads, and exhibited markedly reduced intestinal pathological damage. These results indicate that S1-F-VLP confers robust immune protection against the highly virulent PEDV strain and holds promise as a clinical candidate vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.